Increased thirst and drinking in Huntington's disease and the R6/2 mouse

Brain Research Bulletin

Volumn 76, Issue 1-2, 2008, Pages 70-79

  Wood, Nigel I ^a   Goodman, Anna O G ^b   van der Burg, Jorien M M ^c   Gazeau, Véronique ^a   Brundin, Patrik ^c   Björkqvist, Maria ^c   Petersén, Åsa ^c   Tabrizi, Sarah J ^d   Barker, Roger A ^b   Jennifer Morton, A ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c LUND UNIVERSITY   (Sweden)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Drinking; Hypothalamus; Vasopressin; Xerostomia

Indexed keywords

VASOPRESSIN;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DISEASE COURSE; DRINKING BEHAVIOR; FEMALE; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS; MAJOR CLINICAL STUDY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; THIRST; URINE OSMOLALITY; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; WILD TYPE; XEROSTOMIA;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRINKING; FEMALE; HUMANS; HUNTINGTON DISEASE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OSMOLAR CONCENTRATION; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; QUESTIONNAIRES; THIRST; URINE; VASOPRESSINS; XEROSTOMIA;

EID: 41549091929     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2007.12.007     Document Type: Article

References (35)

1. Abercrombie M., and Johnson M.L. Quantitative histology of Wallerian degeneration: I nuclear population in rabbit sciatic nerve. J. Anat. 80 (1946) 37-50
2. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
3. Björkqvist M., Fex M., Renström E., Wierup N., Petersén A., Gil J., Bacos K., Popovic N., Li J.-Y., Sundler F., Brundin P., and Mulder H. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient ß-cell mass and exocytosis. Hum. Mol. Genet. 14 (2005) 565-574
4. Brunstrom J.M., Tribbeck P.M., and MacRae A.W. The role of mouth state in the termination of drinking behaviour in humans. Physiol. Behav. 68 (2000) 579-583
5. Carter R.J., Hunt M.J., and Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 15 (2000) 925-937
6. Djousse L., Knowlton B., Cupples L.A., Marder K., Shoulson I., and Myers R.H. Weight loss in early stage of Huntington's disease. Neurology 59 (2002) 1325-1330
7. Eisbruch A., Kim H.M., Terrell J.E., Marsh L.H., Dawson L.A., and Ship J.A. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 695-704
8. Gottlieb H.B., Ji L.L., Jones H., Penny M.L., Fleming T., and Cunningham J.T. Differential effects of water and saline intake on water deprivation-induced c-Fos staining in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290 (2006) R1251-R1261
9. Hamilton J.M., Wolfson T., Peavy G.M., Jacobson M.W., and Corey-Bloom J. Rate and correlates of weight change in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 209-212
10. Hansotia P., Wall R., and Berendes J. Sleep disturbances and severity of Huntington's disease. Neurology 35 (1985) 1672-1674
11. Kagel M.C., and Leopold N.A. Dysphagia in Huntington's disease: a 16-year retrospective. Dysphagia 7 (1992) 106-114
12. Kotliarova S., Jana N.R., Sakamoto N., Kurosawa M., Miyazaki H., Nekooki M., Doi H., Machida Y., Wong H.K., Suzuki T., Uchikawa C., Kotliarov Y., Uchida K., Nagao Y., Nagaoka U., Tamaoka A., Oyanagi K., Oyama F., and Nukina N. Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates. J. Neurochem. 93 (2005) 641-653
13. Kremer H.P., and Roos R.A. Weight loss in Huntington's disease. Arch. Neurol. 49 (1992) 349
14. Kremer H.P., Roos R.A., Dingjan G., Marani E., and Bots G.T. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J. Neuropathol. Exp. Neurol. 49 (1990) 371-382
15. Lavin P.J., Bone I., and Sheridan P. Studies of hypothalamic function in Huntington's chorea. J. Neurol. Neurosurg. Psychiatry 44 (1981) 414-418
16. Leopold N.A., and Kagel M.C. Dysphagia in Huntington's disease. Arch. Neurol. 42 (1985) 57-60
17. Luthi-Carter R., Hanson S.A., Strand A.D., Bergstrom D.A., Chun W., Peters N.L., Woods A.M., Chan E.Y., Kooperberg C., Krainc D., Young A.B., Tapscott S.J., and Olson J.M. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11 (2002) 1911-1926
18. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
19. Morales L.M., Estevez J., Suarez H., Villalobos R., Chacin de Bonilla L., and Bonilla E. Nutritional evaluation of Huntington disease patients. Am. J. Clin. Nutr. 50 (1989) 145-150
20. Morton A.J., Wood N.I., Hastings M.H., Hurelbrink C., Barker R.A., and Maywood E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 25 (2005) 157-163
21. Nance M.A., and Sanders G. Characteristics of individuals with Huntington disease in long-term care. Mov. Disord. 11 (1996) 542-548
22. Petersén A., Gil J., Maat-Schieman M.L., Bjorkqvist M., Tanila H., Araujo I.M., Smith R., Popovic N., Wierup N., Norlen P., Li J.Y., Roos R.A., Sundler F., Mulder H., and Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Genet. 14 (2005) 39-47
23. Petit D., Gagnon J.F., Fantini M.L., Ferini-Strambi L., and Montplaisir J. Sleep and quantitative EEG in neurodegenerative disorders. J. Psychosom. Res. 56 (2004) 487-496
24. Popovic V., Svetel M., Djurovic M., Petrovic S., Doknic M., Pekic S., Miljic D., Milic N., Glodic J., Dieguez C., Casanueva F.F., and Kostic V. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur. J. Neurosci. 20 (2004) 451-455
25. Pratley R.E., Salbe A.D., Ravussin E., and Caviness J.N. Higher sedentary energy expenditure in patients with Huntington's disease. Ann. Neurol. 47 (2000) 64-70
26. Quinn L.P., Grundy R.I., Campbell C.A., Collier S., Lawman A., Stean T.O., Billinton A., Parsons A.A., Upton N., Duxon M.S., and Irving E.A. A novel behavioural registration system LABORAS and the social interaction paradigm detect long-term functional deficits following middle cerebral artery occlusion in the rat. Brain Res. 1031 (2005) 118-124
27. Quinn L.P., Stean T.O., Trail B., Duxon M.S., Stratton S.C., Billinton A., and Upton N. LABORAS: Initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour. J. Neurosci. Methods 130 (2003) 83-92
28. Ribchester R.R., Thomson D., Wood N.I., Hinks T., Gillingwater T.H., Wishart T.M., Court F.A., and Morton A.J. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. 20 (2004) 3092-3114
29. Shoulson I., and Fahn S. Huntington disease: clinical care and evaluation. Neurology 29 (1979) 1-3
30. Strand A.D., Baquet Z.C., Aragaki A.K., Holmans P., Yang L., Cleren C., Beal M.F., Jones L., Kooperberg C., Olson J.M., and Jones K.R. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J. Neurosci. 27 (2007) 11758-11768
31. Trejo A., Tarrats R.M., Alonso M.E., Boll M.C., Ochoa A., and Velasquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 20 (2004) 192-196
32. Van de Weerd H.A., Bulthuis R.J., Bergman A.F., Schlingmann F., Tolboom J., Van Loo P.L., Remie R., Bauman V., and Van Zutphen L.F. Validation of a new system for the automatic registration of behaviour in mice and rats. Behav. Process. 53 (2001) 11-20
33. van der Burg J.M.M., Bacos K., Wood N.I., Lindqvist A., Wierup N., Woodman B., Wamsteeker J.I., Smith R., Deierborg T., Kuhar M.J., Bates G.P., Mulder H., Erlanson-Albertsson C., Morton A.J., Brundin P., Petersen A., and Bjorkqvist M. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 29 (2008) 41-51
34. Wiegand M., Moller A.A., Lauer C.J., Stolz S., Schreiber W., Dose M., and Krieg J.C. Nocturnal sleep in Huntington's disease. J. Neurol. 238 (1991) 203-208
35. Yeates K.E., and Morton A.R. Vasopressin antagonists: role in the management of hyponatremia. Am. J. Nephrol. 26 (2006) 348-355